| Parameter . | Number (%) . |
|---|---|
| Average patient age | 56.5 years with range 40–73 years |
| Presentation Type: Screening | 24 (55%) |
| Symptomatic | 20 (45%) |
| Tumour type | N = 47 |
| Invasive NST | 31 (66%) |
| Invasive lobular | 3 (6%) |
| Mixed ductal and lobular | 3 (6%) |
| Metaplastic | 2 (4%) |
| Mucinous | 1 (2%) |
| Tubular | 1 (2%) |
| High-grade DCIS | 6 (13%) |
| Invasive tumour grade | N = 41 |
| 1 | 3 (7%) |
| 2 | 24 (59%) |
| 3 | 14 (34%) |
| Oestrogen receptor status | N = 41 |
| Positive | 35 (85%) |
| Negative | 6 (15%) |
| HER2 receptor status | N = 41 |
| Positive | 8 (20%) |
| Negative | 33 (80%) |
| Mean tumour size | 29 mm (Range 1–65 mm) |
| Surgical management following post-operative breast MRI | N = 47 |
| Mastectomy | 11 |
| Re-excision | 25 |
| Mastectomy after re-excision | 2 |
| No surgery | 11 |
| Parameter . | Number (%) . |
|---|---|
| Average patient age | 56.5 years with range 40–73 years |
| Presentation Type: Screening | 24 (55%) |
| Symptomatic | 20 (45%) |
| Tumour type | N = 47 |
| Invasive NST | 31 (66%) |
| Invasive lobular | 3 (6%) |
| Mixed ductal and lobular | 3 (6%) |
| Metaplastic | 2 (4%) |
| Mucinous | 1 (2%) |
| Tubular | 1 (2%) |
| High-grade DCIS | 6 (13%) |
| Invasive tumour grade | N = 41 |
| 1 | 3 (7%) |
| 2 | 24 (59%) |
| 3 | 14 (34%) |
| Oestrogen receptor status | N = 41 |
| Positive | 35 (85%) |
| Negative | 6 (15%) |
| HER2 receptor status | N = 41 |
| Positive | 8 (20%) |
| Negative | 33 (80%) |
| Mean tumour size | 29 mm (Range 1–65 mm) |
| Surgical management following post-operative breast MRI | N = 47 |
| Mastectomy | 11 |
| Re-excision | 25 |
| Mastectomy after re-excision | 2 |
| No surgery | 11 |
DCIS, ductal carcinoma in situ.
| Parameter . | Number (%) . |
|---|---|
| Average patient age | 56.5 years with range 40–73 years |
| Presentation Type: Screening | 24 (55%) |
| Symptomatic | 20 (45%) |
| Tumour type | N = 47 |
| Invasive NST | 31 (66%) |
| Invasive lobular | 3 (6%) |
| Mixed ductal and lobular | 3 (6%) |
| Metaplastic | 2 (4%) |
| Mucinous | 1 (2%) |
| Tubular | 1 (2%) |
| High-grade DCIS | 6 (13%) |
| Invasive tumour grade | N = 41 |
| 1 | 3 (7%) |
| 2 | 24 (59%) |
| 3 | 14 (34%) |
| Oestrogen receptor status | N = 41 |
| Positive | 35 (85%) |
| Negative | 6 (15%) |
| HER2 receptor status | N = 41 |
| Positive | 8 (20%) |
| Negative | 33 (80%) |
| Mean tumour size | 29 mm (Range 1–65 mm) |
| Surgical management following post-operative breast MRI | N = 47 |
| Mastectomy | 11 |
| Re-excision | 25 |
| Mastectomy after re-excision | 2 |
| No surgery | 11 |
| Parameter . | Number (%) . |
|---|---|
| Average patient age | 56.5 years with range 40–73 years |
| Presentation Type: Screening | 24 (55%) |
| Symptomatic | 20 (45%) |
| Tumour type | N = 47 |
| Invasive NST | 31 (66%) |
| Invasive lobular | 3 (6%) |
| Mixed ductal and lobular | 3 (6%) |
| Metaplastic | 2 (4%) |
| Mucinous | 1 (2%) |
| Tubular | 1 (2%) |
| High-grade DCIS | 6 (13%) |
| Invasive tumour grade | N = 41 |
| 1 | 3 (7%) |
| 2 | 24 (59%) |
| 3 | 14 (34%) |
| Oestrogen receptor status | N = 41 |
| Positive | 35 (85%) |
| Negative | 6 (15%) |
| HER2 receptor status | N = 41 |
| Positive | 8 (20%) |
| Negative | 33 (80%) |
| Mean tumour size | 29 mm (Range 1–65 mm) |
| Surgical management following post-operative breast MRI | N = 47 |
| Mastectomy | 11 |
| Re-excision | 25 |
| Mastectomy after re-excision | 2 |
| No surgery | 11 |
DCIS, ductal carcinoma in situ.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
